|
ISAR-SAFE
Intracoronary Stenting and Antithrombotic Regimen: Safety And efficacy of six months dual antiplatelet therapy after drug-Eluting stenting
Ongoing trial
 |
Author(s) |
Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann F-J, ten Berg JM, Schömig A, Kastrati A |
 |
Title(s) |
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety And eFficacy of 6 months dual antiplatelet therapy after drug-Eluting stenting (ISAR-SAFE) study |
|
Reference(s) |
Am Heart J 2009;157:620–4.e2 |
|
Disease |
Coronary artery disease |
|
Purpose |
To compare the effects of 6- vs 12-month therapy with clopidogrel after implantation of drug-eluting stent |
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
9 months |
|
Patients |
Aim 6000 patients, aged ≥ 18 years, receiving clopidogrel at 6 months after stent implantation |
|
Treatment regimen |
Clopidogrel for 6 months after implantation of drug-eluting stent, then clopidogrel for an additional 6 months, or placebo |
|
Concomitant therapy |
ASA, 85–200 mg/day, in all patients |
|
Results |
Not yet available |
|
|
|
